Cellink AB (publ) (STO:CLNK B) shareholders might be concerned after seeing the share price drop 14% in the last quarter. But looking back over the last year, the returns have actually been rather ...

With today’s 3D bioprinters, two separate extruders are typically used; one for laying down a “bioink” and another for laying down the cells onto that ink. With CELLINK, the cells and the bioink may ...

One day we’ll replace our old knackered organs with brand new ones that are printed out exclusively for us with a 3D printer. And when we do, we’ll quite possibly use a printer like the Cellink Bio X ...

Cellink focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic ...

BLACKSBURG — A lab inside the Virginia Tech Corporate Research Center turned green under the lights of one of Cellink’s 3-D printers on a recent afternoon, a signal that the company’s latest nose was ...

CELLINK today announced its partnership with Made In Space, Inc. (MIS), the industry leader for space manufacturing technologies, to develop advanced bioprinting technology for space. The partnership ...

The recent breakthrough in harvesting pig organs for mammalian heart transplants has put the spotlight back on the efforts of many researchers around the world to help solve the world’s organ shortage ...

Stockholm, April 20, 2020 – Nasdaq (Nasdaq: NDAQ) announces that the trading in Cellink AB’s shares (short name: CLNK B) will commence today on the Nasdaq Stockholm main market. Cellink belongs to the ...

Cellink’s BIO X6, a six-printhead bioprinting platform, offers the capability to combine more materials, cells, and tools to enhance research applications across the bioprinting field. BIO X6, a ...

CELLINK has been granted a patent for a unique cellulose-based bioink technology enabling bioprinting of multiple cell types for cell culturing, tissue engineering and regenerative medicine ...

CELLINK has launched the next part of a multiphase bioink expansion. This phase includes the release of two new bioink series, the expansion of three existing bioink series, the release of a new ...

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today released its first detailed response to the lawsuit Cellink (NASDAQ Stockholm: BICO) filed against it in ...